Targeting the sphingosine 1-phosphate receptor 2 for multiple sclerosis computer-aided drug discovery

Clicks: 1
ID: 285031
2022
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #2,979 of 3,757 articles by views in Malay Journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 3,757 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Multiple sclerosis (MS) continues to affect 2.8 million people worldwide in 2020, and as of yet there is no cure for it. There exist drugs to treat the symptoms of MS, but those that aim to treat the cause of the disease are scarce, as it affects the autoimmune response, and little is known about diseases of this type. Computer-aided drug design (CADD) is a viable method for discovering new drugs, being more cost-effective and efficient than traditional methods, alleviating the need for numerous clinical trials. It can be utilized in discovering hits that can potentially target MS as well. This paper discusses the current state of MS, and the application of computational techniques, and methods in discovering a new drug for it. We utilized various computational software for the visualization of protein and ligand structures, docking simulations and virtual screening, clustering, ADME, and the analysis of top hits in order to discover a drug specifically targeting the sphingolipid-1 receptors (S1PR). Two compounds, trimethyl-[4-[(5-methyl-1,2-oxazol-3-yl)oxy]but-2-ynyl]azanium (Compound 1) and 3-tert-butyl-8-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2,4-dione (Compound 2) were selected for molecular dynamics (MD) simulations, and subsequent analyses to determine their effectiveness in binding to S1PR2.
Reference Key
persistent_1760654411_68f1744b18eb1 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tanada, Noah Rafael Moran
Journal Malay Journal
Year 2022
DOI
DOI not found
URL
https://animorepository.dlsu.edu.ph/etdb_chem/23
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.